Publications by authors named "Dorela Lame"
Article Synopsis
- Immunoglobulin G4-related disease (IgG4-RD) is an immune disorder that leads to organ swelling and fibrosis and can rarely occur alongside primary immune thrombocytopenia (ITP), which is marked by low platelet counts without a clear cause.
- A case study presents a 56-year-old woman with a history of ITP since 2005, who developed IgG4-RD in 2011, requiring various treatments including steroids, azathioprine, and other therapies due to relapses of ITP.
- The patient experienced some improvement with a combination of low-dose prednisone and mycophenolate, but her platelet count remains a concern, suggesting the need for further research into potential links between Ig
Article Synopsis
- Sarcoidosis is a complex disease that can affect multiple organs and may cause severe thrombocytopenia due to factors like hypersplenism and immune-related issues.
- A case of a young male with extreme thrombocytopenia and related symptoms led doctors to rule out infections and hematological disorders, yet initial treatments for immune thrombocytopenia (ITP) did not succeed.
- After trying various therapies, including Romiplostim, the patient's platelet count recovered, and further imaging raised concerns about underlying sarcoidosis as a contributing factor to his condition.
Article Synopsis
- The case discusses a 78-year-old woman with severe leukocytosis and anemia who initially appeared asymptomatic and was hospitalized for a routine check-up.
- After an abdominal ultrasound showed mild splenomegaly, further examinations revealed a significant decline in her cognitive function and multiple brain lesions a week later.
- An autopsy confirmed extreme infiltration of leukemia in various organs, indicating a complex condition potentially classified as an overlap syndrome between atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN), making diagnosis challenging.
Myeloproliferative neoplasms are divided into essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Although ruxolitinib was proven to be effective in reducing symptoms, patients rarely achieve complete molecular remission. Therefore, it is relevant to identify new therapeutic targets to improve the clinical outcome of patients.
View Article and Find Full Text PDF